Advertisement

Topics

Celltrion and Teva Announce FDA Acceptance of BLA for Proposed Biosimilar to Rituxan

11:24 EDT 29 Jun 2017 | Speciality Pharma Journal

INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE)–Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for CT-P10, a proposed Monoclonal Antibody (mAb) biosimilar to Rituxan®1 (rituximab), which is used to treat …

Original Article: Celltrion and Teva Announce FDA Acceptance of BLA for Proposed Biosimilar to Rituxan

NEXT ARTICLE

More From BioPortfolio on "Celltrion and Teva Announce FDA Acceptance of BLA for Proposed Biosimilar to Rituxan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...